Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Oncotarget|December 15, 2015
HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancerNaoki Takegawa, Kimio Yonesaka, Kazuko Sakai, et al.
International Cancer Conference Journal|March 31, 2025
Malignant transformation of an ovarian mature teratoma diagnosed 17 years ago: a case report and literature review of treatment with immune checkpoint inhibitorsAkiho Nagayama, Chiho Miyagawa, Yoko Kashima, et al.
Lung Cancer (Amsterdam, Netherlands)|March 19, 2010
Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancerIsamu Okamoto, Koji Takeda, Haruko Daga, et al.
Cancer Science|October 7, 2016
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210GKohei Shitara, Kimio Yonesaka, Tadamichi Denda, et al.
Oncotarget|October 22, 2016
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1Yoshikane Nonagase, Kimio Yonesaka, Hisato Kawakami, et al.
Investigational New Drugs|May 25, 2012
A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancerYoshikazu Hasegawa, Isamu Okamoto, Ken Takezawa, et al.
Lung Cancer (Amsterdam, Netherlands)|July 2, 2025
Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L studyYoshitaka Zenke, Seiji Niho, Yukihiro Toi, et al.
Scientific Reports|December 22, 2019
Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitorsKimio Yonesaka, Eiji Iwama, Hidetoshi Hayashi, et al.
Cancer Research Communications|March 11, 2026
Constitutive EGFR activation induced by PTPRR downregulation confers resistance to KRAS inhibitorsHiroaki Kanemura, Toshiyuki Takehara, Osamu Maenishi, et al.
The Journal of Clinical Investigation|October 30, 2019
U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activationKoji Haratani, Kimio Yonesaka, Shiki Takamura, et al.
Pageof 7